December 28, 2020 – Some 95% of people have gene variants that may negatively affect their response to at least one drug, leading to unexpected or adverse drug reactions (ADRs) or, if unlucky, to a serious, if not fatal, adverse …

Genetics behind some serious adverse drug reactions (SADRs) Read more »

March 10, 2020 – A widespread assumption is, the people of Asian descent are more prone to serious, sometimes deadly adverse drug reactions, even when taking rather common medications prescribed for gout through to depression. In the ages of genetics …

Are Asians at higher genetic risk of serious adverse events to common medications? Read more »

September 26, 2016 – Toxic epidermal necrolysis (TEN), also known as Lyell’s syndrome, is a rare, life-threatening skin condition that is usually caused by a reaction to drugs. The disease causes the top layer of skin (the epidermis) to detach from the lower layers of the skin …

Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms Read more »

August 30, 2016 – The present article which just appeared in August 2016 issue of  PLOS Medicine illustrates how the inaccurate and biased to say the least the assessment and the reporting of adverse drug reactions by pharmaceutical companies throughout …

Orlistat: Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers Read more »

August 26, 2016 – Eltrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag is approved and on the market under the trade name Promacta in the US …

Eltrombopag (Revolade) can cause severe hepatotoxicity and potentially fatal liver injury Read more »

Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O’Brien SM, Liem AK, McIntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW Blood 2016 Mar; …

Clinical phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL Read more »